Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Rivaroxaban, a direct factor Xa inhibitor, has seldom been used in patients with coronary artery disease. In this analysis, we aimed to systematically compare the efficacy and safety of rivaroxaban in addition to the anti-platelet regimen in patients with coronary artery disease. METHODS...

Descripción completa

Detalles Bibliográficos
Autor principal: Yuan, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932859/
https://www.ncbi.nlm.nih.gov/pubmed/29720261
http://dx.doi.org/10.1186/s40360-018-0209-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932859/
https://www.ncbi.nlm.nih.gov/pubmed/29720261
http://dx.doi.org/10.1186/s40360-018-0209-2

Ejemplares similares